Cardiovascular Outcomes Research Laboratories (CORELAB)Department of Surgery David Geffen School of Medicine at University of California, Los Angeles Los Angeles CA Division of Cardiac Surgery Swedish Medical Center Seattle WA Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer CentersDepartment of Surgery David Geffen School of Medicine at University of California, Los Angeles Los Angeles CA Department of Medicine Statistics Core University of California, Los Angeles Los Angeles CA.
Liver Transpl. 2021 Feb;27(2):200-208. doi: 10.1002/lt.25936. Epub 2020 Dec 31.
Although socioeconomic disparities persist both pre- and post-transplantation, the impact of payer status has not been studied at the national level. We examined the association between public insurance coverage and waitlist outcomes among candidates listed for liver transplantation (LT) in the United States. All adults (age ≥18 years) listed for LT between 2002 and 2018 in the United Network for Organ Sharing database were included. The primary outcome was waitlist removal because of death or clinical deterioration. Continuous and categorical variables were compared using the Kruskal-Wallis and chi-square tests, respectively. Fine and Gray competing-risks regression was used to estimate the subdistribution hazard ratios (HRs) for risk factors associated with delisting. Of 131,839 patients listed for LT, 61.2% were covered by private insurance, 22.9% by Medicare, and 15.9% by Medicaid. The 1-year cumulative incidence of delisting was 9.0% (95% confidence interval [CI], 8.3%-9.8%) for patients with private insurance, 10.7% (95% CI, 9.9%-11.6%) for Medicare, and 10.7% (95% CI, 9.8%-11.6%) for Medicaid. In multivariable competing-risks analysis, Medicare (HR, 1.20; 95% CI, 1.17-1.24; P < 0.001) and Medicaid (HR, 1.20; 95% CI, 1.16-1.24; P < 0.001) were independently associated with an increased hazard of death or deterioration compared with private insurance. Additional predictors of delisting included Black race and Hispanic ethnicity, whereas college education and employment were associated with a decreased hazard of delisting. In this study, LT candidates with Medicare or Medicaid had a 20% increased risk of delisting because of death or clinical deterioration compared with those with private insurance. As more patients use public insurance to cover the cost of LT, targeted waitlist management protocols may mitigate the increased risk of delisting in this population.
尽管在移植前后仍然存在社会经济差距,但在国家层面上尚未研究付款人身份的影响。我们研究了在美国,公共保险覆盖范围与肝移植(LT)候选人等待名单结果之间的关系。所有在 2002 年至 2018 年期间在美国器官共享网络数据库中列出的接受 LT 的成年人(年龄≥18 岁)均包括在内。主要结果是由于死亡或临床恶化而从等待名单中删除。连续变量和分类变量分别使用 Kruskal-Wallis 和卡方检验进行比较。精细和灰色竞争风险回归用于估计与除名相关的风险因素的亚分布风险比(HR)。在 131839 名接受 LT 的患者中,61.2%的人有私人保险,22.9%的人有医疗保险,15.9%的人有医疗补助。具有私人保险的患者的 1 年累积除名率为 9.0%(95%置信区间[CI],8.3%-9.8%),医疗保险为 10.7%(95%CI,9.9%-11.6%),医疗补助为 10.7%(95%CI,9.8%-11.6%)。在多变量竞争风险分析中,医疗保险(HR,1.20;95%CI,1.17-1.24;P<0.001)和医疗补助(HR,1.20;95%CI,1.16-1.24;P<0.001)与私人保险相比,死亡或恶化的风险增加与私人保险独立相关。除名的其他预测因素包括黑人种族和西班牙裔,而大学教育和就业与除名风险降低有关。在这项研究中,与私人保险相比,医疗保险或医疗补助的 LT 候选人因死亡或临床恶化而除名的风险增加了 20%。随着越来越多的患者使用公共保险来支付 LT 的费用,针对等待名单管理协议可能会减轻该人群除名风险的增加。